Efficacy, Safety and Mechanism of Cyclodextrins as Absorption Enhancers in Nasal Delivery of Peptide and Protein Drugs

References

• Adjei A., Sundberg D., Miller J., Chun A. Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm. Res 1992; 9: 244–249
   PubMed Web of Science ®Google Scholar
• Albers E., Müller B. W. Cyclodextrin derivatives in pharmaceutics. Crit. Rev. Ther. Drug Carr. Syst 1995; 12: 311–337
   PubMed Web of Science ®Google Scholar
• Anderberg E. K., Lindmark T., Artursson P. Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm. Res 1993; 10: 857–864
   PubMed Web of Science ®Google Scholar
• Antlsperger G., Schmid G. Toxicological comparison ofcyclodextrins. Proceedings of the Eighth International Symposium On cyleodexlrins, J. Szejtli, L. Szente. Kluwer Academic Publishers, Dordrecht 1996; 149–155
   Google Scholar
• Brewster M. E., Hora M. S., Simpkins J. W., Bodor N. Use of 2-hydroxyl-β-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm. Res 1991; 8: 792–795
   PubMed Web of Science ®Google Scholar
• Chien Y. W., Banga A. K. Potential developments in systemic delivery of insulin. Drug Dev. Ind. Pharm 1989; 15: 1601–1634
   Web of Science ®Google Scholar
• Drejer K., Vaag A., Bech K., Hansen P., Sorensen A. R., Mygind N. Intranasal administration of insulin with phospholipid as absorption enhancer: pharmacokinetics in normal subjects. Diahet. Med 1992; 9: 335–340
   PubMed Web of Science ®Google Scholar
• Duchêne D., Wouessidjewe D. Pharmaceutical uses of cyclodextrins and derivatives. Drug Dev. Ind. Pharm 1990a; 16: 2487–2499
   Web of Science ®Google Scholar
• Duchene D., Wouessidjewe D. Physicochemical characteristics and pharmaceutical uses of cyclodextrin derivatives. Pharm. Technol. Int June, 1990b; 21–29
   Google Scholar
• Ennis R. D., Borden L., Lee W. A. The effects of permeation enhancers on the surface morphology of the rat nasal mucosa: A scanning electron microscopy study. Pharm. Res 1990; 7: 468–475
   PubMed Web of Science ®Google Scholar
• Forbes A. R., Gamsu G. Mucociliary clearance in canine lung during and after general anesthesia. Anesthesiology 1979; 50: 26–29
   PubMed Web of Science ®Google Scholar
• Frank D., Gray J. E., Weaver R. N. Cyclodextrin nephrosis in the rat. Am. J. Pathol 1976; 83: 367
   PubMed Web of Science ®Google Scholar
• Frijlink H. W., Eissens A. C., Hefting N. R., Poelstra K., Lerk C. F., Meijer D. K. F. The effect of parenterally administered cyclodextrins on cholesterol levels in the rat. Pharm. Res 1991; 8: 9–16
   PubMed Web of Science ®Google Scholar
• Garay R. P., Feray J. C., Nazaret C., Fanous K., Villegas M. J., Letavernier J. F. A new approach for the in vitro evaluation of cyclodextrin effects on cellular membranes of human cells. Proceedings 7th International Cyclodextrin Symposium, T. Osa. Komiyama Printing Co., Tokyo 1994; 373–376
   Google Scholar
• Gizurarson S. The relevance of nasal physiology to the design of drug absorption studies. Advan. Drug Del. Rev 1993; 11: 329–347
   Web of Science ®Google Scholar
• Haeberlin B., Gengenbacher T., Meinzer A., Fricker G. Cyclodextrins - Useful excipients for oral peptide administration?. Int. J. Pharm 1996; 137: 103–110
   Web of Science ®Google Scholar
• Hermens W. A. J. J., Hooymans P. M., Verhoef J. C., Merkus F. W. H. M. Effects of absorption enhancers on human nasal tissue ciliary movement in vitro. Pharm. Res 1990; 7: 144–146
   PubMed Web of Science ®Google Scholar
• Hermens W. A. J. J., Belder C. W. J., Merkus J. M. W. M., Hooymans P. M., Verhoef J., Merkus F. W. H. M. Intranasal estradiol administration to oophorectomized women. Eur J. Ohstet. Gvnecol. Reprod. Biol 1991; 40: 35–41
   PubMed Web of Science ®Google Scholar
• Hermens W. A. J. J., Belder C. W. J., Merkus J. M. W. M., Hooymans P. M., Verhoef J., Merkus F. W. H. M. Intranasal administration of estradiol in combination with progesterone to oophorectomized women: a pilot study. Eur. J. Ohstet. Gynecol. Reprod. Biol 1992; 43: 65–70
   PubMed Web of Science ®Google Scholar
• Hilsted J., Madsbad S., Hvidberg A., Rasmussen M. H., Krarup T., Ipsen H., Hansen B., Pedersen M., Djurup R., Oxenboll B. Intranasal insulin therapy: The clinical realities. Diahetologica 1995; 38: 680–684
   PubMed Web of Science ®Google Scholar
• Hochman J. H., Fix J. A., LeCluyse E. L. In vitro and in vivo analysis of the mechanism of absorption enhancement by palmityolcarnitine. J. Pharmacol. Ex. Ther 1994; 269: 813–821
   PubMed Web of Science ®Google Scholar
• Hosoya K. I., Kubo H., Natsume H., Sugibayashi K., Morimoto Y., Yamashita S. The structural barrier of absorptive mucosae: site difference of the permeability of fluorescein isothiocyanate-labelled dextran in rabbits. Biopharm. Drug Disp 1993; 14: 685–696
   PubMed Web of Science ®Google Scholar
• Hovgaard L., Bronsted H. Drug delivery studies in Caco-2 monolayers. IV. Absorption enhancers effects of cyclodextrins. Pharm. Res 1995; 12: 1328–1332
   PubMed Web of Science ®Google Scholar
• Ilium L. Nasal delivery. The use of animal models to predict performance in man. J. Drug Targ 1996; 3: 427–442
   PubMed Web of Science ®Google Scholar
• Ilium L., Davis S. Intranasal insulin: clinical pharmacokinetics. Clin. Pharmacokinet 1992; 23: 30–41
   PubMed Web of Science ®Google Scholar
• Irie T., Wakamatsu K., Arima H., Aritomi H., Uekama K. Enhancing effects of cyclodextrins on nasal absorption of insulin in rats. Int. J. Pharm 1992; 84: 129–139
   Web of Science ®Google Scholar
• Irwin W. J., Dwivedi A. K., Holbrook P. A., Dey M. J. The effect of cyclodextrins on the stability of peptides in nasal enzymic systems. Pharm. Res 1994; 11: 1698–1703
   PubMed Web of Science ®Google Scholar
• Gill Jabbal I., Fisher A. N., Hinchcliffe M., Whetstone J., Farraj N., De Ponti R., Ilium L. Cyclodextrins as protection agents against enhancer damage in nasal delivery systems II. Effect on in vivo absorption of insulin and histopathology of nasal membrane. Eur. J. Pharm. Sci 1994; 1: 237–248
   Web of Science ®Google Scholar
• Jacobs M. A., Schreuder R. H., Jap-A-Joe K., Nauta J. J., Andersen P. M., Heine R. J. The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers. Diabetes 1993; 42: 1649–1655
   PubMed Web of Science ®Google Scholar
• Jodal I., Nanasi P., Szejtli J. Investigation in the hemolytic effect of the cyclodextrin derivatives. Proceedings of the Fourth International Symposium on Cyclodextrins, O. Huber, J. Szejtli. Kluwer Academic Publishers, Dordrecht 1988; 407–413
   Google Scholar
• Kagatani S., Shinoda T., Fukui M., Ohmura T., Hasumi S., Sonobe T. Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats. Pharm. Res 1996; 13: 739–743
   PubMed Web of Science ®Google Scholar
• Kilsdonk E. P. C., Yancey P. G., Stoudt G. W., Bangerter F. W., Johnson W. J., Phillips M. C., Rothblat G. H. Cellular cholesterol efflux mediated by cyclodextrins. J. Biol. Chem 1995; 270: 17250–17256
   PubMed Web of Science ®Google Scholar
• Koizumi K., Okada Y., Kuboza Y., Utamura T. Inclusion complexes of poorly water-soluble drugs with glycosyl-cyclodextrins. Chem. Pharm. Bull 1987; 35: 3413–3418
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy R., Wolka A. M., Shao Z., Mitra A. K. Cyclodextrins as mucosal absorption promoters IV. Evaluation of nasal mucotoxicity. Eur. J. Pharm. Biopharm 1995; 41: 296–301
   Web of Science ®Google Scholar
• Landa J. F., Hirsch J. A., Lebeaux M. I. Effects of topical and general anesthetics on tracheal mucuos velocity in sheep. J. Appl. Physiol 1975; 38: 946–948
   PubMed Web of Science ®Google Scholar
• Lee W. A. Permeation enhancers for the nasal delivery of protein and peptide therapeutics. Biopharm. Drug Disp Nov/Dec., 1990; 22–25
   Google Scholar
• Lee W. A., Narog B. A., Patapoff T. W., Wang Y. J. Intranasal bioavailability of insulin powder formulations: Effect of permeation enhancer to protein ratio. J. Pharm. Sci 1991; 80: 725–729
   PubMed Web of Science ®Google Scholar
• Leroy-Lechat F., Skiba M., Wouessidjewe D., Duchêne D. Cytotoxicity of cyclodextrins and derivatives. Minutes of the 6th International Symposium on Cyclodextrins, A. R. Hedges. Editions de Santé, Paris 1992; 292–297
   Google Scholar
• Leroy-Lechat F., Wouessidjewe D., Andreux J. P., Puisieux F., Duchene D. Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivatives. Int. J. Pharm 1994; 101: 97–103
   Web of Science ®Google Scholar
• Lovatt M., Cooper A., Camilleri P. Energetics of cyclodextrin-induced dissociation of insulin. Pruceedings of the Eighth International Symposium on Cyclodextrins, J. Szejtli, L. Szente. Kluwer Academic Publishers, Dordrecht 1996; 361–364
   Google Scholar
• Marttin E., Verhoef J. C., Romeijn S. G., Merkus F. W. H. M. Effects of absorption enhancers on rat nasal epithelium in vivo: release of marker compounds in the nasal cavity. Pharm. Res 1995; 12: 1151–1157
   PubMed Web of Science ®Google Scholar
• Marttin E., Verhoef J. C., Romeijn S. G., Zwart P., Merkus F. W. H. M. Acute histopathological effects of benzalkonium chloride and absorption enhancers on rat nasal epithelium in vitro. Int. J. Pharm 1996; 141: 151–160
   Web of Science ®Google Scholar
• Marttin E., Romeijn S. G., Verhoef J. C., Merkus F. W. H. M. Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits. J. Pharm. Sci 1997a; 86: 802–807
   PubMed Web of Science ®Google Scholar
• Marttin E., Schipper N. G. M., Verhoef J. C., Merkus F. W. H. M. Nasal mucociliary clearance as a factor in nasal drug delivery. Advan. Drug Del. Rev 1998; 29: 13–38
   PubMed Web of Science ®Google Scholar
• Marttin E., Verhoef J. C., Cullander C., Romeijn S. G., Nageikerke J. F., Merkus F. W. H. M. Confocal laser scanning microscopic visualization of the transport of dextrans after nasal administration to rats: effects of absorption enhancers. Pharm. Res 1997b; 14: 631–637
   PubMed Web of Science ®Google Scholar
• Matsubara K., Abe K., Irie T., Uekama K. Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats. J. Pharm. Sci 1995; 84: 1295–1300
   PubMed Web of Science ®Google Scholar
• McMartin C., Hutchinson L. E. F., Hyde R., Peters G. E. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci 1987; 76: 535–540
   PubMed Web of Science ®Google Scholar
• Merkus F. W. H. M., Verhoef J., Romeijn S. G., Schipper N. G. M. Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats. Pharm. Res 1991a; 8: 588–592
   PubMed Web of Science ®Google Scholar
• Merkus F. W. H. M., Verhoef J., Romeijn S. G., Schipper N. G. M. Interspecies differences in the nasal absorption of insulin. Pharm. Res 1991b; 8: 1343
   PubMed Web of Science ®Google Scholar
• Merkus F. W. H. M., Schipper N. G. M., Hermens W. A. J. J., Romeijn S. G., Verhoef J. C. Absorption enhancers in nasal drug delivery: efficacy and safety. J. Controlled Rei 1993; 24: 201–208
   Web of Science ®Google Scholar
• Merkus F. W. H. M., Marttin E., Romeijn S. G., Verhoef J. In situ perfusion is an unrealistic approach to assess the effects of absorption enhancers on nasal epithelium. Eur J. Pharm. Biopharm 1996a; 42: 159
   Web of Science ®Google Scholar
• Merkus F. W. H. M., Schipper N. G. M., Verhoef J. C. The influence of absorption enhancers on the intranasal insulin absorption in normal and diabetic subjects. J. Controlled Rel 1996b; 41: 69–75
   Web of Science ®Google Scholar
• Moses A. C., Gordon G. S., Carey M. C., Fier J. S. Insulin administered intranasally as an insulin-bile salt aerosol. Diabetes 1983; 32: 1040–1047
   PubMed Web of Science ®Google Scholar
• Nakamuta H., Nitta T., Hoshino T., Koida M. Glucocorticoid-induced osteopenia in rats: histomorphometrical and microarchitectural characterization and calcitonin effect. Biol. Pharm. Bull 1996; 19: 217–219
   PubMed Web of Science ®Google Scholar
• Nakanishi K., Nadai T., Masada M., Miyajima K. Effect of cyclodextrins on biological membrane. I. Effect of cyclodextrins on the absorption of a non-absorbable drug from the rat small intestine and rectum. Chem. Pharm. Bull 1990; 38: 1684–1687
   PubMed Web of Science ®Google Scholar
• Nakanishi K., Masukawa T., Miyajima K. The interaction with cyclodextrin and biological membrane on the drug absorption. Proceedings 7th International Cyclodextrins Symposium, T. Osa. Komiyama Printing Co., Tokyo 1994; 377–381
   Google Scholar
• Neufeld E. B., Cooney A. M., Pitha J., Dawidowicz E. A., Dwyert N. K., Pentchev P. F., Blanchette-Mackie E. J. Intracellular trafficking of cholesterol monitored with a cyclodextrin. J. Biol. Chem 1996; 271: 21604–21613
   PubMed Web of Science ®Google Scholar
• Nitta T., Hoshino T., Koida M., Nakmuta H. Histomorphometrical evaluation of anti-osteopenic effect of nasal salmon calcitonin in type 1 osteoporotic model of rats. Biol. Pharm. Bull 1996; 19: 214–216
   PubMed Web of Science ®Google Scholar
• Nolte M. S., Taboga C., Salamon E., Moses A., Longenecker J., Flier J., Karam J. H. Biological activity of nasally administered insulin in normal subjects. Horm. Metabol. Res 1990; 22: 170–174
   PubMed Web of Science ®Google Scholar
• Ohtani Y., Irie T., Uekama K., Fukunaga K., Pitha J. Differentialeffectsofalpha-, beta-, and gamma-cyclodextrin on human erythrocytes. Eur. J. Biochem 1989; 186: 17–22
   PubMedGoogle Scholar
• Okada Y., Kubota Y., Koizumi K., Hizukuri S., Ohfuji T., Ogata K. Some properties and the inclusion behaviour of branched cyclodextrins. Chem. Pharm. Bull 1988; 36: 2176–2185
   PubMed Web of Science ®Google Scholar
• Olivier P., Verwaerde F., Hedges A. R. Subchronic toxicity of orally administered beta-cyclodextrin in rats. J. Am. Coll. Toxicol 1991; 10: 407–419
   Google Scholar
• Perrin J. H., Field F. P., Hansen D. A., Mufson R. A., Torosian G. β-cyclodextrin as an aid to peritoneal dialysis. Renal toxicity of β-cyclodextrin in the rat. Res. Comm. Chem. Pathol. Pharmacol 1978; 19: 373
   PubMedGoogle Scholar
• Pitha J. Pharmacological role of hydroxypropyl cyclodextrins. New Trends in Cyclodextrins and Derivatives, D. Duchene. Editons de Sante, Paris 1991; 353
   Google Scholar
• Pontiroli A. E., Alberetto M., Pajetta E., Calderara A., Pozza G. Human insulin plus sodium glycocholate in a nasal spray formulation: improved bioavalability and effectiveness in normal subjects. Diab. Metah 1987; 13: 441–443
   PubMed Web of Science ®Google Scholar
• Pontiroli A. E., Calderara A., Pozza G. Intranasal drug delivery; Potential advantages and limitations from a clinical pharmacokinetic perspective. Clin. Pharmacokinet 1989; 17: 299–307
   PubMed Web of Science ®Google Scholar
• Rajewski R. A., Stella V. J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci 1996; 85: 1142–1169
   PubMed Web of Science ®Google Scholar
• Reeuwijk H. J. E. M., Irth H., Tjaden U. R., Merkus F. W. H. M., Van der Greef J. Liquid chromatographic determination of β-cyclodextrin derivatives based on fluorescence enhancement after inclusion complexation. J. Chroma-togr 1993; 614: 95–101
   PubMed Web of Science ®Google Scholar
• Romeijn S. G., Verhoef J. C., Marttin E., Merkus F. W. H. M. The effect of nasal drug formulations on ciliary beating in vitro. Int. J. Pharm 1996; 135: 137–145
   Web of Science ®Google Scholar
• Sakr F. M. Nasal administration of glucagon combined with dimethyl-β-cyclodextrin: comparison of pharmacokinetics and pharmacodynamics of spray and powder formulations. Int. J. Pharm 1996; 132: 189–194
   Google Scholar
• Schipper N. G. M., Verhoef J., Romeijn S. G., Merkus F. W. H. M. Absorption enhancers in nasal insulin delivery and their influence on nasal ciliary functioning. J. Controlled Rei 1992; 21: 173–186
   Web of Science ®Google Scholar
• Schipper N. G. M., Romeijn S. G., Verhoef J. C., Merkus F. W. H. M. Nasal insulin delivery with dimethyl-/?-cyclodextrin as an absorption enhancer in rabbits: powder more effective than liquid formulations. Pharm. Res 1993a; 10: 682–686
   PubMed Web of Science ®Google Scholar
• Schipper N. G. M., Verhoef J. C., De Lannoy L. M., Romeijn S. G., Brakkee J. H., Wiegant V. M., Gispen W. H., Merkus F. W. H. M. Nasal administration of an ACTH(4–9) peptide analog with dimethyl-β-cyclodextrin as an absorption enhancer: pharmacokinetics and dynamics. Br. J. Pharmacol 1993b; 110: 1335–1340
   PubMed Web of Science ®Google Scholar
• Schipper N. G. M., Verhoef J. C., Romeijn S. G., Merkus F. W. H. M. Methylated β-cyclodextrins are able to improve the nasal absorption of salmon calcitonin. Cacif. Tissue Int 1995; 56: 280–282
   PubMed Web of Science ®Google Scholar
• Shao Z., Krishnamoorthy R., Mitra A. K. Cyclodextrins as nasal absorption promoters of insulin - mechanistic evaluations. Pharm. Res 1992; 9: 1157–1163
   PubMed Web of Science ®Google Scholar
• Silber G., Proud D., Warner J., Nacleno R., Kagey-Sobotka A., Lichtenstein L., Eggleston P. In vivo release of inflammatory mediators by hyperosmolar solutions. Rev. Respir. Dis 1988; 137: 606–612
   PubMed Web of Science ®Google Scholar
• Sim T. C., Grant A., Hilsmeier K. A., Fukuda Y., Alam R. Proinflammatory cytokines in nasal secretions of allergic subjects after antigen challenge. Am. J. Resp. Crit. Care Med 1994; 149: 339–344
   PubMed Web of Science ®Google Scholar
• Stadel J. M., Hoyle K., Naclerio R. M., Roshak A., Chilton F. H. Characterization of phospholipase A2 from human nasal lavage. Am. J. Respir. Cell Mol. Biol 1994; 11: 408–413
   Google Scholar
• Strattan C. E. Cyclodextrins and biological macromole-cules. Biopharm Nov/Dec, 1991; 44–51
   Google Scholar
• Szabo P., Ferenczy T., Seifözö J., Liptáp A. Absorption and elimination of cyclodextrin derivatives by rabbits and rats. Proceedings of the 1st International Symposium on Cyclodextrins, J. Szejtli. Kluwer Academic Publishers, Dordrecht 1982; 115
   Google Scholar
• Szatmári I., Vargay Z. Pharmacokinetics of dimethyl-β-cyclodextrin in rats. Proceedings of the Fourth International Symposium on Cyclodextrins, O. Huber, J. Szejtli. Kluwer Academic Publishers, Dordrecht 1988; 407–413
   Google Scholar
• Szejtli J. Dimethyl-beta-cyclodextrin as parenteral drug carrier. J. Incl. Phen 1983; 1: 135–150
   Google Scholar
• Szejtli J. Cyclodextrins in drug formulations. Pharm. Technol. Int 1991a; 2: 15–22
   Google Scholar
• Szejtli J. Cyclodextrins in drug formulations. Pharm. Technol. Int 1991b; 3: 16–24
   Google Scholar
• Szejtli J. Medicinal applications of cyclodextrins. Med. Res. Rev 1994; 14: 353–363
   PubMed Web of Science ®Google Scholar
• Thompson D. O. Cycodextrins - Enabling Excipients: Their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Can. Syst 1997; 14: 1–104
   PubMed Web of Science ®Google Scholar
• Totterman A. M., Schipper N. G. M., Thompson D. O., Mannermaa J. P. Intestinal safety of water-soluble β-cyclodextrins in paediatric solutions of spironolactone: effects on human intestinal epithelial Caco-2 cells. J. Pharm. Pharmacol 1997; 49: 43–48
   PubMed Web of Science ®Google Scholar
• Trinadha C., Pitlia J., Lindberg B., Lindberg J. Distribution of substituents in O-(2-hydroxypropyl) derivatives of cyclomalto-oligosaccharides (cyclodextrins): Influence of increasing substitution, of the base used in the preparation, and of macrocyclic size. Carbohydrate Research 1992; 233: 99–107
   Google Scholar
• Uekama K., Otagiri M. Cyclodextrins in drug carrier systems. Crit. Rev. Ther. Drug Carr. Syst 1987; 3: 1–40
   PubMed Web of Science ®Google Scholar
• Van de Donk H. J. M., Zuidema J., Merkus F. W. H. M. Correlation between the sensitivity of the ciliary beat frequency of human adenoid tissue and chicken embryo tracheas for some drugs. Rhinology 1982; 20: 81–87
   PubMedGoogle Scholar
• Watanabe Y., Matsumoto Y., Kawamoto K., Yazawa S., Matsumoto M. Enhancing effects of cyclodextrins on nasal absorption of insulin and its duration in rabbits. Chem. Pharm. Bull 1992; 40: 3100–3104
   PubMed Web of Science ®Google Scholar
• Watanabe Y., Matsumoto Y., Yamaguchi M., Kikuchi R., Takayama K., Nomura H., Maruyama K., Maisumoto M. Absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and blood leukocyte dynamics following intranasal administration in rabbits. Biol. Pharm. Bull 1993; 16: 93–95
   PubMed Web of Science ®Google Scholar
• Watanabe Y., Matsumoto Y., Kikuchi R., Kiriyama M., Ito R., Matsumoto M., Nomura H., Maruyama K. Absorption and blood leukocyte dynamics of recombinant human granulocyte colony-stimulating factor (rhG-CSF) from intranasally administered preparations containing rhG-CSF and cyclodextrins in rabbits. Int. J. Pharm 1994; 110: 93–97
   Web of Science ®Google Scholar
• Yamamoto M., Yoshida A., Hirayama F., Uekama K. Some physicochemical properties of branched β-cyclo-dextrins and their inclusion characteristics. Int. J. Pharm 1989; 46: 217–222
   Google Scholar
• Yancey P. G., Rodrigueza W. V., Kilsdonk E. P. C., Stoudt G. W., Johnson W. J., Phillips M. C., Rothblat G. H. Cellular cholesterol efflux mediated by cyclodextrins. Demonstration of kinetic pools and mechanism of efflux. J. Biol. Chem 1996; 271: 16026–16034
   PubMed Web of Science ®Google Scholar
• Yeagle P. L. Cholesterol and the cell membrane. Biochim. Biophys. Acta 1985; 822: 267–287
   PubMed Web of Science ®Google Scholar
• Yoshida A., Arima H., Uekama K., Pitha J. Pharmaceutical evaluation of hydroxyalkyl ethers of beta-cyclodextrins. Int. J. Pharm 1988; 46: 217–222
   Web of Science ®Google Scholar